QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

BCAX

QT80Bicara Therapeutics Inc. Common Stock
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
23.23
+0.31+1.35%
OverviewShort InterestFilings
BCAXQT80Bicara Therapeutics Inc. Common Stock·NASDAQ
OverviewShort InterestFilings
23.23+1.35%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand-
Perf Week9.16%
Market Cap1.26BForward P/E-EPS next Y-3.70Insider Trans-Shs Float-Perf Month15.98%
Enterprise Value933.53MPEG0.20EPS next Q-Inst Own-Short Float-Perf Quarter23.63%
Income-141876711.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y27.99%
Sales-P/B2.71EPS next Y-6.17%ROA-28.42%Short Interest-Perf YTD38.03%
Book/sh-P/C-EPS next 5Y-ROE-35.89%52W High24.25 -4.21%Perf Year140.23%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-33.77%52W Low8.48 173.94%Perf 3Y-
Dividend Est.-EV/EBITDA-5.94Sales past 3/5Y-Gross Margin0.00%Volatility3.55% 3.41%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)1.11Perf 10Y-
Dividend Ex-Date-Quick Ratio13.85Sales Y/Y TTM-Profit Margin0.00%RSI (14)64.16Recom2.40
Dividend Gr. 3/5Y-Current Ratio13.85EPS Q/Q-SMA209.64%Beta1.11Target Price31.25
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA506.51%Rel Volume3.60Prev Close22.92
Employees55LT Debt/Eq0.00Earnings-SMA20029.95%Avg Volume537.46KPrice23.23
IPO DateSep 13, 2024Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA2.05Volume1,934,590Change1.35%
Analyst Ratings
DateActionAnalystRatingTarget
May-12-26ReiteratedMorgan StanleyOverweight$35 → $37
May-12-26ReiteratedGoldman SachsNeutral$14 → $18
May-11-26InitiatedGuggenheimBuy$42
Feb-11-26ReiteratedGoldman Sachs$14
Jan-08-26InitiatedBTIGBuy$28
Dec-17-25InitiatedMizuhoNeutral$18
Aug-22-25ReiteratedH.C. Wainwright$41 → $40
May-23-25UpgradeWells FargoUnderweight → Equal Weight$8.00
Mar-27-25ReiteratedStifel Nicolaus$47 → $48
Oct-08-24InitiatedMorgan StanleyOverweight$35
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other31199
Research and Development1256431
Other Operating Expense0-10
Operating Income-156-82-40
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-18-1512
Net Income Before Taxes-138-68-52
Income Taxes
000
Consolidated Net Income-138-68-52
Net Income From Continuing Operations-138-68-52
Net Income-138-68-52
EPS (Recurring)-2.52-1.25-1.00
EPS (Basic, Before Extraordinaries)-2.52-1.25-1.00
EPS (Diluted)-2.52-1.25-1.00
EBITDA-138-68-52
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding555452
Market Capitalization926——
Operating Lease Expense
———
Insider Trading Volume
$24.77$21.80$18.84$15.88$12.91● Close Price0.00M1.20M2.40M3.60M4.80MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Hyep IvanChief Financial OfficerMay 21 '26Option Exercise3.7918,40069,732154,555May 26 12:00 AM
Hyep IvanChief Financial OfficerMay 21 '26Sale20.429,200187,883145,355May 26 12:00 AM
Mazumdar ClaireChief Executive OfficerMay 18 '26Option Exercise3.7930,000113,694377,152May 20 12:00 AM
Mazumdar ClaireChief Executive OfficerMay 18 '26Sale20.0415,000300,579362,152May 20 12:00 AM
Cohlhepp RyanPresident and COOMay 15 '26Option Exercise3.7916,00060,636204,141May 18 12:00 AM
Cohlhepp RyanPresident and COOMay 15 '26Sale20.2912,500253,649191,641May 18 12:00 AM
Raben DavidChief Medical OfficerApr 27 '26Option Exercise3.7911,00041,68860,786Apr 28 12:00 AM
Raben DavidChief Medical OfficerApr 27 '26Sale22.885,500125,83055,286Apr 28 12:00 AM
Hyep IvanChief Financial OfficerApr 21 '26Option Exercise3.7918,40069,732154,555Apr 22 12:00 AM
Hyep IvanChief Financial OfficerApr 21 '26Sale23.009,200211,614145,355Apr 22 12:00 AM
Mazumdar ClaireChief Executive OfficerApr 20 '26Option Exercise3.7930,000113,694377,152Apr 20 12:00 AM
Mazumdar ClaireChief Executive OfficerApr 20 '26Sale23.6115,000354,146362,152Apr 20 12:00 AM
Mazumdar ClaireChief Executive OfficerApr 16 '26Option Exercise4.5445,520206,718558,432Apr 20 12:00 AM
Cohlhepp RyanPresident and COOApr 15 '26Option Exercise3.7916,00060,636208,641Apr 17 12:00 AM
Cohlhepp RyanPresident and COOApr 15 '26Sale23.0112,500287,591196,141Apr 17 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR